ASCO 2020 Sarcoma In Depth

ASCO 2020 Sarcoma In-Depth

Worse Outcomes With Irinotecan and Temolozomide in Ewing Sarcoma

Irinotecan and temozolomide led to inferior clinical outcomes for patients with recurrent and primary refractory Ewing sarcoma, a multiarm trial found.

Standard Chemotherapy Regimen in US Improved Outcomes in Ewing Sarcoma

A chemotherapy regimen that is standard in the US for patients with Ewing sarcoma appeared to improve outcomes, a randomized phase 3 trial showed.

Immune-Related Adverse Events Linked to Better Outcomes in Sarcoma

Patients with advanced sarcoma who developed immune-related adverse events after immune checkpoint blockade were more likely to have a clinical benefit.

Binimetinib Combo Shows Clinical Activity in Advanced GIST

Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.

Trial Under Way for Novel T-Cell Product in Advanced Synovial Sarcoma

A phase 2 trial is under way to evaluate an investigational autologous T-cell product in patients with advanced synovial sarcoma as well as other tumor types.

Trial Under Way for PARP Inhibitor Combo in Uterine Leiomyosarcoma

A single-arm phase II clinical trial is underway to evaluate temozolomide and olaparib as a treatment combination for patients with advanced uterine leiomyosarcoma.